A trial looking at mini stem cell transplants for myelodysplastic syndrome and acute myeloid leukaemia (FB - ATG)
Cancer type:
Status:
Phase:
This trial was looking at reduced intensity stem cell transplants using thymoglobulin. It was for people who had poor risk myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
If you can't have full stem cell transplant, you may have a mini transplant. The chemotherapy is less intensive, so they are sometimes called reduced intensity transplants.
More about this trial
Doctors already used the drugs fludarabine, busulphan and alemtuzumab (MabCampath) for mini transplants. In this trial they were looking at a different combination of drugs – fludarabine, busulphan and thymoglobulin.
Thymoglobulin is a drug that suppresses the immune system. This means that it could help stop the new stem cells from attacking parts of your body, a possible complication called graft versus host disease (GVHD).
The aims of this trial were to see
- How well fludarabine, busulphan and thymoglobulin helped to stop
MDS 
and AML coming back after a mini transplant - What the side effects were
Summary of results
This trial was never finished so there are no results available. The researchers were unable to collect data from enough patients.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Ghulam J Mufti
Supported by
Experimental Cancer Medicine Centre (ECMC)
Genzyme Therapeutics
Kings College Hospital NHS Foundation Trust
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
